Boundless Bio Inc. BOLD 深 滬
等待開盤 06-24 09:30:00 美东时间
2.60
+1.200
+85.71%
華盛通- 最 高2.75
- 今 開2.40
- 成交量 6548.59万股
- 最 低 2.25
- 昨 收 1.40
- 總市值 5840.67万
- 52周最高 2.75
- 市盈率 靜 --
- 換手率 291.51%
- 52周最低 0.9612
- 委 比 0.00%
- 總股本 2246.41万
- 歷史最高 15.24
- 量 比 681.08
- 振 幅 35.71%
- 歷史最低 0.9612
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Crude Oil Down Over 1%; US Manufacturing PMI Surges In June
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 500 points on Tuesday. The Dow traded down 0.04% to 51,694.44 while the NASDAQ fell 1.91% to 25,665.85. The S&P 500 also fell, dropping, 1.27% to 7,377.89. Leading and Lagging Sectors Consumer staples shares ju...
今天 00:02
Dow Falls Over 300 Points; Korn Ferry Earnings Top Views
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.62% to 51,390.66 while the NASDAQ fell 1.88% to 25,675.75. The S&P 500 also fell, dropping, 1.39% to 7,370.98. Leading and Lagging Sect...
06-23 21:49
Boundless Bio to Merge with Serapha Bio, Restructure Operations
Boundless Bio Inc. ( ($BOLD) ) has provided an announcement. On June 22, 2026, ...
06-23 21:32
Boundless Bio shareholders elect Class II directors at annual meeting
Boundless Bio shareholders elect Class II directors at annual meeting Shareholders met on June 15, 2026. Two Class II directors were selected to serve through the 2029 annual meeting. KPMG LLP was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. Dis
06-17 22:49
Boundless Bio Halts Early Cancer Trial, Resetting Expectations for BOLD
Boundless Bio Inc. ($BOLD) announced an update on their ongoing clinical study....
06-09 00:31
Boundless Bio Q1 EPS $(0.60) Beats $(0.64) Estimate
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(0.64) by 4.76 percent. This is a 15.49 percent increase over losses of $(0.71) per share from the
05-08 19:11
Boundless Bio Reveals Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers,
04-18 04:52
Boundless Bio Terminates Major Long-Term San Diego Lease
The latest announcement is out from Boundless Bio Inc. ( ($BOLD) ). On April 13...
04-14 05:55
Boundless Bio To Present Oral Kinesin Degrader Program At The AACR Annual Meeting 2026
Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers,
03-18 04:55
Boundless Bio Q4 EPS $(0.58) Misses $(0.52) Estimate
Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.52) by 11.54 percent. This is a 21.62 percent increase over losses of $(0.74) per share from
03-09 19:13
